A living WHO guideline on drugs for covid-19
dc.contributor.author | Agarwal, Arnav | en_ZA |
dc.contributor.author | Rochwerg, Bram | en_ZA |
dc.contributor.author | Lamontagne, François | en_ZA |
dc.contributor.author | Siemieniuk, Reed AC | en_ZA |
dc.contributor.author | Agoritsas, Thomas | en_ZA |
dc.contributor.author | Askie, Lisa | en_ZA |
dc.contributor.author | Lytvyn, Lyubov | en_ZA |
dc.contributor.author | Leo, Yee-Sin | en_ZA |
dc.contributor.author | Macdonald, Helen | en_ZA |
dc.contributor.author | Zeng, Linan | en_ZA |
dc.contributor.author | Amin, Wagdy | en_ZA |
dc.contributor.author | Barragan, Fabian A Jaimes | en_ZA |
dc.contributor.author | Bausch, Frederique J. | en_ZA |
dc.contributor.author | Burhan, Erlina | en_ZA |
dc.contributor.author | Calfee, Carolyn S. | en_ZA |
dc.contributor.author | Cecconi, Maurizio | en_ZA |
dc.contributor.author | Chanda, Duncan | en_ZA |
dc.contributor.author | Dat, Vu Quoc | en_ZA |
dc.contributor.author | De Sutter, An | en_ZA |
dc.contributor.author | Du, Bin | en_ZA |
dc.contributor.author | Freedman, Stephen | en_ZA |
dc.contributor.author | Geduld, Heike | en_ZA |
dc.contributor.author | Gee, Patrick | en_ZA |
dc.contributor.author | Gotte, Matthias | en_ZA |
dc.contributor.author | Harley, Nerina | en_ZA |
dc.contributor.author | Hashmi, Madiha | en_ZA |
dc.contributor.author | Hunt, Beverley | en_ZA |
dc.contributor.author | Jehan, Fyezah | en_ZA |
dc.contributor.author | Kabra, Sushil K. | en_ZA |
dc.contributor.author | Kanda, Seema | en_ZA |
dc.contributor.author | Kim, Yae-Jean | en_ZA |
dc.contributor.author | Kissoon, Niranjan | en_ZA |
dc.contributor.author | Krishna, Sanjeev | en_ZA |
dc.contributor.author | Kuppalli, Krutika | en_ZA |
dc.contributor.author | Kwizera, Arthur | en_ZA |
dc.contributor.author | Castro-Rial, Marta Lado | en_ZA |
dc.contributor.author | Lisboa, Thiago | en_ZA |
dc.contributor.author | Lodha, Rakesh | en_ZA |
dc.contributor.author | Mahaka, Imelda | en_ZA |
dc.contributor.author | Manai, Hela | en_ZA |
dc.contributor.author | Mino, Greta | en_ZA |
dc.contributor.author | Nsutebu, Emmanuel | en_ZA |
dc.contributor.author | Preller, Jacobus | en_ZA |
dc.contributor.author | Pshenichnaya, Natalia | en_ZA |
dc.contributor.author | Qadir, Nida | en_ZA |
dc.contributor.author | Relan, Pryanka | en_ZA |
dc.contributor.author | Sabzwari, Saniya | en_ZA |
dc.contributor.author | Sarin, Rohit | en_ZA |
dc.contributor.author | Shankar-Hari, Manu | en_ZA |
dc.contributor.author | Sharland, Michael | en_ZA |
dc.contributor.author | Shen, Yinzhong | en_ZA |
dc.contributor.author | Ranganathan, Shalini S. | en_ZA |
dc.contributor.author | Souza, Joao P. | en_ZA |
dc.contributor.author | Stegemann, Miriam | en_ZA |
dc.contributor.author | Swanstrom, Ronald | en_ZA |
dc.contributor.author | Ugarte, Sebastian | en_ZA |
dc.contributor.author | Uyeki, Tim | en_ZA |
dc.contributor.author | Venkatapuram, Sridhar | en_ZA |
dc.contributor.author | Vuyiseka, Dubula | en_ZA |
dc.contributor.author | Wijewickrama, Ananda | en_ZA |
dc.contributor.author | Tran, Lien | en_ZA |
dc.contributor.author | Zeraatkar, Dena | en_ZA |
dc.contributor.author | Bartoszko, Jessica J. | en_ZA |
dc.contributor.author | Ge, Long | en_ZA |
dc.contributor.author | Brignardello-Petersen, Romina | en_ZA |
dc.contributor.author | Owen, Andrew | en_ZA |
dc.contributor.author | Guyatt, Gordon | en_ZA |
dc.contributor.author | Diaz, Janet | en_ZA |
dc.contributor.author | Kawano-Dourado, Leticia | en_ZA |
dc.contributor.author | Jacobs, Michael | en_ZA |
dc.contributor.author | Vandvik, Per Olav | en_ZA |
dc.date.accessioned | 2022-05-27T10:10:06Z | |
dc.date.available | 2022-05-27T10:10:06Z | |
dc.date.issued | 2022-09 | |
dc.description | CITATION: Agarwal, A. et al. 2022. A living WHO guideline on drugs for covid-19. British Medical Journal, 370. doi:10.1136/bmj.m3379 | |
dc.description | The original publication is available at https://jcp.bmj.com/ | |
dc.description.abstract | This living guideline by Arnav Agarwal and colleagues (BMJ 2020;370:m3379, doi:10.1136/bmj.m3379) was last updated on 22 April 2022, but the infographic contained two dosing errors: the dose of ritonavir with renal failure should have read 100 mg, not 50 mg; and the suggested regimen for remdesivir should have been 3 days, not 5-10 days. The infographic has now been corrected. | en_ZA |
dc.description.version | Publishers version | |
dc.format.extent | 19 pages : illustrations | |
dc.identifier.citation | Agarwal, A. et al. 2022. A living WHO guideline on drugs for covid-19. British Medical Journal, 370. doi:10.1136/bmj.m3379 | |
dc.identifier.issn | 1472-4146 (online) | |
dc.identifier.issn | 0021-9746 (print) | |
dc.identifier.other | doi:10.1136/bmj.m3379 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/125256 | |
dc.language.iso | en_ZA | en_ZA |
dc.rights.holder | Authors retain copyright | |
dc.subject | COVID-19 (Disease) -- Prevention -- Government policy | en_ZA |
dc.subject | Coronavirus infections -- Prevention | en_ZA |
dc.subject | Covid-19 guidelines | en_ZA |
dc.title | A living WHO guideline on drugs for covid-19 | en_ZA |
dc.type | Article | en_ZA |